LYEL Lyell Immunopharma Inc
Price (delayed)
$1.33
Market cap
$340.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.82
Enterprise value
$260.1M
Highlights
Lyell Immunopharma's debt has decreased by 11% YoY and by 3.3% QoQ
The EPS rose by 9% since the previous quarter and by 2.4% year-on-year
The revenue has dropped by 100% year-on-year and by 21% since the previous quarter
The gross profit has plunged by 100% YoY and by 21% from the previous quarter
Key stats
What are the main financial stats of LYEL
Market
Valuations
Earnings
Shares outstanding
256M
Market cap
$340.48M
Enterprise value
$260.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.6
Price to sales (P/S)
6,290.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,816.6
Revenue
$54,000
EBIT
-$210.26M
EBITDA
-$190.17M
Free cash flow
-$159.01M
Per share
Balance sheet
Liquidity
EPS
-$0.82
Free cash flow per share
-$0.62
Book value per share
$2.22
Revenue per share
$0
TBVPS
$2.56
Total assets
$654.14M
Total liabilities
$87.64M
Debt
$53.32M
Equity
$566.5M
Working capital
$468.95M
Debt to equity
0.09
Current ratio
16.19
Quick ratio
15.91
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-352,172.2%
Gross margin
100%
Net margin
-389,368.5%
Operating margin
-417,870.4%
Return on assets
-29.1%
Return on equity
-33.3%
Return on invested capital
-36.7%
Return on capital employed
-33.7%
Return on sales
-389,368.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYEL stock price
How has the Lyell Immunopharma stock price performed over time
Intraday
-4.32%
1 week
15.65%
1 month
9.02%
1 year
-17.9%
YTD
-31.44%
QTD
-8.28%
Financial performance
How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$54,000
Gross profit
$54,000
Operating income
-$225.65M
Net income
-$210.26M
Gross margin
100%
Net margin
-389,368.5%
The revenue has dropped by 100% year-on-year and by 21% since the previous quarter
The gross profit has plunged by 100% YoY and by 21% from the previous quarter
The operating margin has declined by 18% since the previous quarter
Lyell Immunopharma's net margin has decreased by 16% QoQ
Growth
What is Lyell Immunopharma's growth rate over time
Valuation
What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.6
P/S
6,290.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,816.6
The EPS rose by 9% since the previous quarter and by 2.4% year-on-year
Lyell Immunopharma's equity has decreased by 23% YoY and by 6% from the previous quarter
The stock's P/B is 10% less than its last 4 quarters average of 0.7
The revenue has dropped by 100% year-on-year and by 21% since the previous quarter
LYEL's price to sales (P/S) is 39% more than its last 4 quarters average of 4737.2
Efficiency
How efficient is Lyell Immunopharma business performance
Lyell Immunopharma's ROIC has decreased by 38% YoY but it has increased by 4.2% from the previous quarter
The ROE has contracted by 26% YoY
The ROA is down by 26% year-on-year but it is up by 2% since the previous quarter
The return on sales has declined by 16% since the previous quarter
Dividends
What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYEL.
Financial health
How did Lyell Immunopharma financials performed over time
The total assets has declined by 22% year-on-year and by 6% since the previous quarter
The total liabilities has declined by 11% year-on-year and by 3.8% since the previous quarter
Lyell Immunopharma's debt is 91% lower than its equity
Lyell Immunopharma's equity has decreased by 23% YoY and by 6% from the previous quarter
The debt to equity is up by 13% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.